Neat Launches Subscription Service for Zoom Customers Outside the US and Announces Additional Investment from Zoom
Neat, a Norwegian company whose pioneering team have been at the cutting edge of video communications for decades, today announced its Neat as a Service (NaaS) subscription offering. NaaS makes it quick and easy for Zoom customers outside the US to deploy Neat hardware devices in their meeting spaces. Neat and Zoom have also disclosed that Zoom Video Communications, Inc. (NASDAQ: ZM) has made an additional financial investment in Neat.
"Zoom and Neat together are making it easy for customers to expand their video conferencing capabilities. Our additional investment in Neat reflects our conviction that Neat's devices are an outstanding complement to Zoom's communications platform," said Eric S. Yuan, Zoom CEO. "We believe Neat offers innovative technology that ensures Zoom customers enjoy an incredible meeting room experience."
Aligned with Zoom's recently introduced Hardware as a Service (HaaS), NaaS is provided directly by Neat and expands the reach of Zoom HaaS beyond the US, enabling Zoom customers globally to consume Neat devices. Among other things, it's an ideal solution for customers with offices and teams scattered throughout different countries, as they can ensure a consistent global experience for all users.
As the new normal forces people around the world to adapt their ways of working, both in offices and remotely, video conferencing is proving to be a key tool in supporting continued productivity and driving stronger collaboration. NaaS makes it seamless for customers with a Zoom Rooms license to equip their meeting spaces with any of Neat's world-class devices: Neat Bar and Neat Pad, and Neat Board when it begins shipping at the end of October. With easy ordering and set up, customers can quickly enjoy all the benefits of deploying Zoom Rooms the Neat way, including receiving all the latest software releases and support from Zoom.
"Zoom customers globally are transitioning back to a mix of office and remote work, and need a scalable, cost-effective way to quickly expand their Zoom deployments in their meeting spaces," said Jeff Smith, Head of Zoom Rooms, Zoom. "Neat's innovative devices deliver a great user experience and are easy to install and manage. NaaS builds on that by giving customers the purchasing flexibility and choice they need."
"Subscription models such as Neat as a Service are the future of video conferencing since they eliminate expensive up-front costs and the complexity of deployment and ongoing support," said Roopam Jain, Industry Director, Unified Communications and Collaboration at Frost and Sullivan. "Video meetings are a better way to connect and collaborate. Particularly today, users need video that just works, whether they are in their home offices or meeting rooms."
Customers currently pay for their Zoom Rooms licenses through a subscription service from Zoom. With NaaS, they can use a subscription model for Neat devices as well, making the budgeting and managing of their Zoom Rooms even simpler.
NaaS is available now at neat.no and offers a 24-month plan with flexible payment options so customers can select the plan that best suits their requirements and budget. Neat Bar subscriptions start from as low as US$ 100/mo with an annual billing option. After the initial 24-month term, customers can then choose to upgrade their Neat system for the latest model with the newest hardware technology. Customers can also easily add further Neat devices to their existing plan to keep everything on a single contract.
"Neat was designed for Zoom, with the sole purpose of delivering a delightful meeting room experience to Zoom customers. We have achieved that by providing Zoom customers around the globe with our beautifully designed, simple to set up, feature-rich devices," said Simen Teigre, Neat CEO. "NaaS is the next step in our mission, offering a flexible subscription service that allows businesses to expand their Zoom solution with Zoom Rooms in a hassle-free way."
About Neat
Neat designs simple and elegant video meeting devices that just work. The company was founded in Oslo, Norway, by a team that for decades have shaped game-changing innovations for some of the most recognized brands in video communications. All Neat products are available to buy directly online from neat.no and ship globally. Offering unique features, they are easy to set up and use, making Zoom Rooms the smoothest and best it's ever been. For more information on Zoom Rooms the Neat way, visit neat.no or @neat_no.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005220/en/
Contact information
Amy Martin
Media Relations
amy.martin@neat.no
+1 408 391 5194
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
